blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2361908

EP2361908 - Pyrimidine compounds useful for the treatment of CNS diseases [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  29.04.2016
Database last updated on 07.10.2024
Most recent event   Tooltip29.04.2016Application deemed to be withdrawnpublished on 01.06.2016  [2016/22]
Applicant(s)For all designated states
AbbVie Deutschland GmbH & Co KG
Max-Planck-Ring 2a
65205 Wiesbaden / DE
[2013/42]
Former [2011/35]For all designated states
Abbott GmbH & Co. KG
Max-Planck-Ring 2
65205 Wiesbaden / DE
Inventor(s)01 / Geneste, Hervé
Rehbachstr. 42
67141 Neuhofen / DE
02 / Haupt, Andreas
Schaelzigweg 52
68723 Schwetzingen / DE
03 / Braje, Wilfried
Knollstrasse 50
67061 Ludwigshafen / DE
04 / Lubisch, Wilfried
Hirtenaue 38
69118 Heidelberg / DE
05 / Steiner, Gerd
Oberer Waldweg 1
67281 Kirchheim / DE
 [2011/46]
Former [2011/35]01 / Geneste, Hervé
Rehbachstr. 42
67141 Neuhofen / DE
02 / Haupt, Andreas
Schaelzigweg 52
68723 Schwetzingen / DE
03 / Braje, Wilfried
Meerfeldstr. 52
68163 Mannheim / DE
04 / Lubisch, Wilfried
Hirtenaue 38
69118 Heidelberg / DE
05 / Steiner, Gerd
Oberer Waldweg 1
67281 Kirchheim / DE
Representative(s)Reitstötter Kinzebach
Patentanwälte
Im Zollhof 1
67061 Ludwigshafen / DE
[N/P]
Former [2011/35]Reitstötter - Kinzebach
Patentanwälte Ludwigsplatz 4
67059 Ludwigshafen / DE
Application number, filing date11167864.503.06.2005
[2011/35]
Priority number, dateDE2004102735804.06.2004         Original published format: DE102004027358
[2011/35]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report 
No.:EP2361908
Date:31.08.2011
Language:DE
[2011/35]
Search report(s)(Supplementary) European search report - dispatched on:EP03.08.2011
ClassificationIPC:C07D401/12, C07D413/12, C07D417/12, A61K31/506, A61P25/36
[2011/35]
CPC:
C07D417/12 (EP,US); A61P25/00 (EP); A61P25/18 (EP);
A61P25/24 (EP); A61P25/36 (EP); A61P43/00 (EP);
C07D401/12 (EP,US); C07D413/12 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2011/35]
TitleGerman:Zur Behandlung von zentralnervösen Erkrankungen geeignete Pyrimidinverbindungen[2011/35]
English:Pyrimidine compounds useful for the treatment of CNS diseases[2011/35]
French:Composés de pyrimidine utiles pour le traitement de troubles du SNC[2011/35]
Examination procedure29.02.2012Amendment by applicant (claims and/or description)
29.02.2012Examination requested  [2012/20]
05.01.2016Application deemed to be withdrawn, date of legal effect  [2016/22]
28.01.2016Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2016/22]
Parent application(s)   TooltipEP05750829.3  / EP1751116
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20050750829) is  18.05.2009
Fees paidRenewal fee
27.06.2011Renewal fee patent year 03
27.06.2011Renewal fee patent year 04
27.06.2011Renewal fee patent year 05
27.06.2011Renewal fee patent year 06
21.07.2011Renewal fee patent year 07
31.03.2012Renewal fee patent year 08
31.03.2013Renewal fee patent year 09
31.03.2014Renewal fee patent year 10
Penalty fee
Additional fee for renewal fee
30.06.201511   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[AD]WO9725324  (BASF AG [DE], et al) [AD] 1-19 * page 1, lines 5-9 * * Seite 4, Formel I * * page 5, lines 11-19 * * page 6, lines 25-35 * * page 7, lines 5-25 * * page 20, line 25 - page 21, line 20 *;
 [A]  - A. ORJALES ET AL., "New 3-benzoisothiazolyl and 3-benzoisoxazolylpiperazine derivatives with atypical antipsychotic binding profile", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY., EDITIONS SCIENTIFIQUE ELSEVIER; PARIS, FR, (2002), vol. 37, pages 721 - 730, XP004383155 [A] 1-19 * page 722; figures 1,2 *

DOI:   http://dx.doi.org/10.1016/S0223-5234(02)01391-0
by applicantWO9602519
 WO9602520
 WO9602249
 WO9602246
 WO9902503
 WO0042036
 WO0042037
 WO0042038
 WO0067847
 WO9725324
 DE10304870
 DE3800386
 EP0244697
 DE19728996
 DE19735410
    - "The Dopamine D3 Receptor as a Target for Antipsychotics", J.C. SCHWARTZ ET AL., Novel Antipsychotic Drugs, RAVEN PRESS, (1992), pages 135 - 144
    - M. DOOLEY ET AL., DRUGS AND AGING, (1998), vol. 12, pages 495 - 514
    - J.N. JOYCE, "The Dopamine D3 Receptor as a Therapeutic Target for Antipsychotic and Antiparkinsonian Drugs", PHARMACOLOGY AND THERAPEUTICS, (2001), vol. 90, pages 231 - 59
    - P. SOKOLOFF ET AL., "Localization and Function of the D3 Dopamine Receptor", ARZNEIM. FORSCH./DRUQ RES., (1992), vol. 42, no. 1, page 224, XP000250098
    - P. SOKOLOFF ET AL., "Molecular Cloning and Characterization of a Novel Dopamine Receptor (D3) as a Target for Neuroleptics", NATURE, (1990), vol. 347, doi:doi:10.1038/347146a0, page 146, XP002027883

DOI:   http://dx.doi.org/10.1038/347146a0
    - Fortschritte der Arzneimittelforschung, BIRKHäUSER VERLAG, (1966), vol. 10, page 224
    - "Analogie zu bekannten Verfahren hergestellt werden, wie beispielsweise beschrieben", J. ORG. CHEM., (1981), vol. 46, no. 18, page 3719
    - J. HETEROCYCL. CHEM., (2001), vol. 38, no. 4, pages 961 - 964
    - J. HETEROCYCL. CHEM., (1983), vol. 20, no. 3, page 663.666
    - J. MED. CHEM., (1986), vol. 29, no. 10, pages 1832 - 1840
    - J. MED. CHEM., (2000), vol. 43, pages 3718 - 3735
    - J. MED. CHEM., (1986), vol. 29, no. 1, pages 1 - 8
    - CHEM. PHARM. BULL., (2000), vol. 49, no. 7, pages 822 - 829
    - ORG. LETT., (2002), vol. 4, no. 16, pages 2691 - 2694
    - J. ORG. CHEM., (1972), vol. 37, page 2849
    - TETRAHEDRON, (2001), vol. 57, pages 9199 - 9225
    - J. HETEROCYCL. CHEM., (2001), vol. 38, no. 4, pages 961 - 4
    - J. MED. CHEM., (1986), vol. 29, pages 1832 - 40
    - J. MED. CHEM., (2000), vol. 43, pages 3718 - 35
    - CHEM. PHARM. BULL., (2001), vol. 49, pages 822 - 9
    - J. HETEROCYCL. CHEM, (1983), vol. 20, pages 663 - 6
    - ORG. LETT, (2002), vol. 4, pages 261 - 4
    - ORG. LETT., (2002), vol. 4, pages 261 - 4
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.